ProShares Ultra Nasdaq Biotechnology (BIB) Leveraged/Inverse
$109.80
▼ -0.67 (-0.61%)
1-day change
$62.04 – $126.40
52-week range
Holdings data is not available for this fund yet.
BIB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Performance as of Oct. 2, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▼ -9.84% | ▼ -9.78% |
| 3M | ▲ +2.77% | ▲ +2.84% |
| 6M | ▲ +34.28% | ▲ +34.37% |
| YTD | ▲ +37.63% | ▲ +37.74% |
| 1Y | ▲ +73.21% | ▲ +73.64% |
| 3Y | ▲ +135.47% | ▲ +142.03% |
| 5Y | ▲ +20.16% | ▲ +23.54% |
| Max | ▲ +1362.31% | ▲ +1406.10% |
Volatility 1Y42.75%
Volatility 3Y41.86%
Max drawdown 3Y
-45.99%
Beta 3Y0.85
Sharpe 1Y*1.50
Total return assumes dividends are reinvested. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
Last month (May 2026)
-$4.8M
Quarter ending May 2026
-$13.9M
Trailing 12 months
-$12.0M
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 267 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| ImmunityBio, Inc. | 45256X103 | $286K | 0.39 | 38,008 | EC | US |
| Vaxcyte, Inc. | 92243G108 | $273K | 0.37 | 5,321 | EC | US |
| Alkermes plc | · | $260K | 0.35 | 6,163 | EC | IE |
| Immunovant, Inc. | 45258J102 | $251K | 0.34 | 7,523 | EC | US |
| Kymera Therapeutics, Inc. | 501575104 | $246K | 0.33 | 3,017 | EC | US |
| Protagonist Therapeutics, Inc. | 74366E102 | $235K | 0.32 | 2,361 | EC | US |
| Mirum Pharmaceuticals, Inc. | 604749101 | $226K | 0.31 | 2,231 | EC | US |
| PTC Therapeutics, Inc. | 69366J200 | $226K | 0.31 | 3,062 | EC | US |
| Rhythm Pharmaceuticals, Inc. | 76243J105 | $223K | 0.30 | 2,526 | EC | US |
| Spyre Therapeutics, Inc. | 00773J202 | $214K | 0.29 | 2,905 | EC | US |
| Cogent Biosciences, Inc. | 19240Q201 | $210K | 0.28 | 6,002 | EC | US |
| CRISPR Therapeutics AG | · | $199K | 0.27 | 3,550 | EC | CH |
| CG oncology, Inc. | 156944100 | $195K | 0.26 | 3,123 | EC | US |
| Scholar Rock Holding Corp. | 80706P103 | $186K | 0.25 | 3,773 | EC | US |
| Centessa Pharmaceuticals plc | 152309100 | $176K | 0.24 | 4,423 | EC | GB |
| Caris Life Sciences, Inc. | 142152107 | $174K | 0.24 | 10,431 | EC | US |
| Ligand Pharmaceuticals, Inc. | 53220K504 | $171K | 0.23 | 736 | EC | US |
| Xenon Pharmaceuticals, Inc. | 98420N105 | $168K | 0.23 | 3,074 | EC | CA |
| Apogee Therapeutics, Inc. | 03770N101 | $167K | 0.23 | 2,028 | EC | US |
| Indivior Pharmaceuticals, Inc. | 45579U109 | $167K | 0.23 | 4,624 | EC | US |
| Travere Therapeutics, Inc. | 89422G107 | $161K | 0.22 | 3,409 | EC | US |
| Amneal Pharmaceuticals, Inc. | 03168L105 | $153K | 0.21 | 11,632 | EC | US |
| Twist Bioscience Corp. | 90184D100 | $152K | 0.21 | 2,266 | EC | US |
| Erasca, Inc. | 29479A108 | $147K | 0.20 | 11,444 | EC | US |
| Newamsterdam Pharma Co. NV | · | $143K | 0.19 | 4,252 | EC | NL |
| Crinetics Pharmaceuticals, Inc. | 22663K107 | $138K | 0.19 | 3,872 | EC | US |
| ACADIA Pharmaceuticals, Inc. | 004225108 | $137K | 0.19 | 6,303 | EC | US |
| Veracyte, Inc. | 92337F107 | $136K | 0.18 | 2,938 | EC | US |
| Edgewise Therapeutics, Inc. | 28036F105 | $135K | 0.18 | 3,966 | EC | US |
| Beam Therapeutics, Inc. | 07373V105 | $124K | 0.17 | 3,767 | EC | US |
| Denali Therapeutics, Inc. | 24823R105 | $123K | 0.17 | 5,863 | EC | US |
| 10X Genomics, Inc. | 88025U109 | $123K | 0.17 | 4,351 | EC | US |
| Dyne Therapeutics, Inc. | 26818M108 | $118K | 0.16 | 6,087 | EC | US |
| Structure Therapeutics, Inc. | 86366E106 | $113K | 0.15 | 2,880 | EC | KY |
| Tango Therapeutics, Inc. | 87583X109 | $109K | 0.15 | 4,978 | EC | US |
| Oruka Therapeutics, Inc. | 687604108 | $105K | 0.14 | 1,789 | EC | US |
| GRAIL, Inc. | 384747101 | $103K | 0.14 | 1,439 | EC | US |
| Alumis, Inc. | 022307102 | $101K | 0.14 | 4,674 | EC | US |
| Arcutis Biotherapeutics, Inc. | 03969K108 | $98K | 0.13 | 4,587 | EC | US |
| Disc Medicine, Inc. | 254604101 | $98K | 0.13 | 1,411 | EC | US |
| Supernus Pharmaceuticals, Inc. | 868459108 | $98K | 0.13 | 2,120 | EC | US |
| Ideaya Biosciences, Inc. | 45166A102 | $96K | 0.13 | 3,246 | EC | US |
| Vera Therapeutics, Inc. | 92337R101 | $94K | 0.13 | 2,636 | EC | US |
| Tarsus Pharmaceuticals, Inc. | 87650L103 | $93K | 0.13 | 1,573 | EC | US |
| Relay Therapeutics, Inc. | 75943R102 | $93K | 0.13 | 6,606 | EC | US |
| Mineralys Therapeutics, Inc. | 603170101 | $92K | 0.13 | 2,925 | EC | US |
| Definium Therapeutics, Inc. | 24477V105 | $89K | 0.12 | 3,685 | EC | CA |
| Enliven Therapeutics, Inc. | 29337E102 | $87K | 0.12 | 2,196 | EC | US |
| Adaptive Biotechnologies Corp. | 00650F109 | $86K | 0.12 | 5,692 | EC | US |
| Ultragenyx Pharmaceutical, Inc. | 90400D108 | $85K | 0.12 | 3,571 | EC | US |
Dividends 13 payments
0.20%TTM yield
$0.23TTM payout / share
Quarterly
(est.)
| Ex-date | Amount / share |
|---|---|
| Sept. 23, 2026 | $0.0830 |
| March 25, 2026 | $0.0070 |
| Dec. 24, 2025 | $0.1350 |
| Sept. 24, 2025 | $0.1810 |
| June 25, 2025 | $0.1710 |
| March 26, 2025 | $0.1310 |
| Dec. 23, 2024 | $0.3960 |
| Sept. 25, 2024 | $0.1530 |
| June 26, 2024 | $0.2650 |
| March 20, 2024 | $0.0400 |
| Dec. 20, 2023 | $0.0380 |
| Dec. 22, 2022 | $0.0200 |
| Sept. 21, 2010 | $0.0110 |
Institutional owners (13F) 22 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785,973 | 21.94% | 7,802 | Shares | June 30, 2026 |
| Capital Investment Advisors, LLC | $599,013 | 16.72% | 5,946 | Shares | June 30, 2026 |
| Kaizen Financial Strategies | $535,554 | 14.95% | 5,315 | Shares | June 30, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413,034 | 11.53% | 4,100 | Call option | June 30, 2026 |
| Palumbo Wealth Management LLC | $402,960 | 11.25% | 4,000 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $302,220 | 8.44% | 3,000 | Call option | June 30, 2026 |
| Jump Financial, LLC | $257,189 | 7.18% | 2,553 | Shares | June 30, 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102,957 | 2.87% | 1,022 | Shares | June 30, 2026 |
| FRANKLIN RESOURCES INC | $70,115 | 1.96% | 696 | Shares | June 30, 2026 |
| PNC Financial Services Group, Inc. | $50,370 | 1.41% | 500 | Shares | June 30, 2026 |
| Ashton Thomas Private Wealth, LLC | $37,576 | 1.05% | 373 | Shares | June 30, 2026 |
| Truvestments Capital LLC | $12,593 | 0.35% | 125 | Shares | June 30, 2026 |
| Axiom Investment Management LLC | $5,037 | 0.14% | 50 | Shares | June 30, 2026 |
| Qube Research & Technologies Ltd | $4,936 | 0.14% | 49 | Shares | June 30, 2026 |
| SIMPLEX TRADING, LLC | $1,309 | 0.04% | 13 | Shares | June 30, 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0.01% | 2,400 | Shares | June 30, 2026 |
| Rockefeller Capital Management L.P. | $201 | 0.01% | 2 | Shares | June 30, 2026 |
| MORGAN STANLEY | $131 | 0.00% | 1 | Shares | June 30, 2026 |
| UBS Group AG | $101 | 0.00% | 1 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0.00% | 1 | Shares | June 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0.00% | 198 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $0 | 0.00% | 1 | Shares | June 30, 2026 |